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Many people compromise the quality of their lives in order to function on a day to day basis. There are several
treatments that are available in alleviating symptoms related to seasonal allergies, but many people have
difficulty adhering to certain recommended regimens. Intranasal corticosteroids have been thought of as the
first line of therapy in the treatment of seasonal allergies, but these require daily treatments. Systemic
antihistamines, on the other hand, provide allergic relief on an as-needed basis, but are subject to a higher
possibility of side effects as they are systemically metabolized. Topical antihistamines are a class of
medications that could possibly provide similar, if not better, effectiveness in symptomatic control of seasonal
allergies.
Methods: The focus of this study was to review clinical trials providing comparison between topical
antihistamines and systemic antihistamines. Clinical trials within the last fifteen years comparing topical
antihistamines with systemic antihistamines and with placebos, were carefully selected and analyzed. Double-
blinded and randomized clinical trials of specific topical antihistamines and systemic antihistamines were
identified by a systematic literature search using MEDLINE, CINAHL, and PUBMED search engines.
Results: Based on the seven randomized, double-blinded, and placebo controlled clinical trials, the efficacy of
topical antihistamines was significantly greater than systemic antihistamines. Both topical and systemic
antihistamines significantly improved symptoms compared to placebo.
Conclusion: Overall, topical and systemic antihistamines reduced seasonal allergy symptoms, particularly
allergic rhinoconjunctivitis. This review confirms the effectiveness of topical antihistamines when compared
to systemic antihistamines.
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Abstract   
 
 
Background:  It has been estimated that seasonal allergies affect up to approximately 44% of 
the population.  Many people compromise the quality of their lives in order to function on a day 
to day basis.  There are several treatments that are available in alleviating symptoms related to 
seasonal allergies, but many people have difficulty adhering to certain recommended regimens.  
Intranasal corticosteroids have been thought of as the first line of therapy in the treatment of 
seasonal allergies, but these require daily treatments.  Systemic antihistamines, on the other 
hand, provide allergic relief on an as-needed basis, but are subject to a higher possibility of side 
effects as they are systemically metabolized.  Topical antihistamines are a class of medications 
that could possibly provide similar, if not better, effectiveness in symptomatic control of 
seasonal allergies.    
 
Methods:  The focus of this study was to review clinical trials providing comparison between 
topical antihistamines and systemic antihistamines.  Clinical trials within the last fifteen years 
comparing topical antihistamines with systemic antihistamines and with placebos, were carefully 
selected and analyzed.  Double-blinded and randomized clinical trials of specific topical 
antihistamines and systemic antihistamines were identified by a systematic literature search 
using MEDLINE, CINAHL, and PUBMED search engines. 
 
Results:  Based on the seven randomized, double-blinded, and placebo controlled clinical trials, 
the efficacy of topical antihistamines was significantly greater than systemic antihistamines.  
Both topical and systemic antihistamines significantly improved symptoms compared to placebo.   
 
Conclusion:  Overall, topical and systemic antihistamines reduced seasonal allergy symptoms, 
particularly allergic rhinoconjunctivitis.  This review confirms the effectiveness of topical 
antihistamines when compared to systemic antihistamines.   
 
Keywords:  seasonal allergic rhinitis, allergic conjunctivitis, azelastine, olopatadine, cetirizine, 
loratadine, desloratadine 
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Topical antihistamines in the treatment of seasonal allergic 
rhinoconjunctivitis with equal or greater effectiveness when 
compared to systemic antihistamines in monotherapy 
 
 
INTRODUCTION 
 
 Seasonal allergies impact the lives of many people and can severely affect the quality of 
life in day to day activities.  It is estimated that allergies affect up to 44% of the United States 
population.1  In 1997, estimates showed that direct costs related to allergies totaled 
approximately $4.5 billion/year along with 3.8 million missed work and school days.1  Many 
people generally side with the belief that a systemic medication works best in controlling allergic 
symptoms while not being fully apprised of the fact that other treatment modalities are available 
to them that do not require systemic absorption for effectiveness. 
 Generally speaking, allergies can be categorized into perennial and seasonal allergies.  
Causes of perennial allergies may include dust mites, cat and dog dander, and mold.  Seasonal 
allergies usually occur during specific times of the year in response to certain allergens that are 
present in the environment.  For example, in the northwest United States, grass pollen is widely 
prevalent during the months of May to July.  Populations sensitive to grass allergens may 
develop symptoms during these months.  Perennial allergies are thought to be more difficult to 
treat compared to seasonal allergies which can be managed medically in anticipation of the 
seasonal months. 
 Allergies are known to be a humoral mediated response of the immune system triggered 
by an allergen.  When an allergen, such as pollen from grass or ragweed, triggers a 
hyperresponsive reaction in a hypersensitive person, a cascade of events unfolds.   
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 The allergen initially forms peptides which cause cytokines to be formed.  IgE, the 
allergy driven class of immunoglobulin antibodies, is formed in response to these cytokines by B 
cells.  These antibodies bind to mast cells and basophils causing a release of granules within the 
cell.  The granules contain histamine and leukotrienes among many other allergic and 
inflammatory mediators.  Histamine binds to certain receptors that have been identified 
throughout the body.  These inflammatory mediators, in turn, cause a series of allergic reactions.  
Common allergic reactions can involve edema of the tissues (such as in the face), oral mucosa, 
sneezing, rhinorrhea, redness, tearing and swelling of the conjunctiva, dermatitis, and sometimes 
even bronchoconstriction of the airway. 
 Seasonal allergies have historically been treated with first-generation systemic 
antihistamines like diphenhydramine (Benadryl).  These were effective, but also had a side effect 
profile of causing sedation and drowsiness.  Many people had difficulty functioning in their daily 
routines because of these sedative effects.  Second-generation oral antihistamines, such as 
loratadine (Claritin) and cetirizine (Zyrtec) were then developed with a less sedating side effect 
profile.  Other methods of medical management involve intranasal corticosteroids such as 
fluticasone (Flonase).  Nasal corticosteroids involve a daily regimen and take about a week to 
take effect with optimal drug levels peaking at two weeks.   Corticosteroids provide a localized 
anti-inflammatory effect in the nasal and sinus pathways.  Antihistamine nasal sprays and eye 
drops work within minutes and are localized to the site of action.  These topical antihistamines 
do not require daily usage and they provide the benefits of controlling allergic symptoms 
localized to the nasal and sinus passages and they also help control ocular symptoms without 
having to be systemically absorbed.  Table 1 lists common topical and oral antihistamines 
available either over-the-counter or by prescription. 
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 Many patients have difficulty adhering to the daily regimen of using an intranasal 
corticosteroid.  Other patients avoid using oral antihistamines to control allergy symptoms in 
order to avoid systemic absorption and the risk of side effects such as somnolence and fatigue.  
Although topical antihistamines have been proven to provide symptomatic relief of allergies, 
many patients are under the presumption that seasonal allergies are best treated in the form of a 
pill without recognizing the potential adverse systemic effects of the medication.  Because some 
patients cannot tolerate steroids, whether it is due to epistaxis, adherence, or intolerability, it 
seems reasonable to prescribe topical antihistamines over systemic antihistamines to provide 
immediate effective relief from seasonal allergic rhinoconjunctivitis.  The aim of this review is to 
evaluate the effectiveness of topical antihistamines compared to systemic antihistamines in 
monotherapeutic symptomatic treatment rhinoconjunctivitis.   
 
METHOD 
 
 An exhaustive literature search was executed using MEDLINE, PUBMED, and CINAL 
to identify studies treating patients with seasonal allergies and comparing the use of topical 
antihistamines to systemic antihistamines.   
 As it is difficult to locate several randomized placebo-controlled trials comparing topical 
antihistamines to systemic antihistamines, multiple different methods were used in the search.  
This review is part of a series that included antihistamine medications and seasonal allergic 
rhinitis and conjunctivitis search terms.  Selected studies also had to meet the criteria of 
involving the treatment of patients suffering from seasonal allergic rhinoconjunctivitis 
independent of perennial allergies.  Broad definitions of allergies and treatments were used to 
include a large pool of studies.  From there, specific terms such as intranasal antihistamines, 
ocular antihistamines, and oral antihistamines were used to narrow the search without much 
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success.  To further focus the review, a specific topical antihistamine, such as azelastine and a 
systemic antihistamine such as cetirizine, were used in the search.  Each topical medication was 
paired with a different systemic medication until most pairings were exhausted.  Certain trials 
were also included if they investigated the efficacy of a topical version of the same oral drug in 
the treatment of seasonal allergies.   
 Studies that were excluded involved patients on other medications which could alter the 
results of the effects of antihistamines.  Several studies were excluded based on the fact that 
corticosteroids were given in conjunction with antihistamines as part of the study design.  Also 
excluded were reviews that included research of co-morbid conditions in patients with allergies, 
such as autoimmune conditions, pulmonary conditions, and cardiac illnesses, among others.  
Single histamine trials were also not pertinent to this review.  Additionally, adjunctive studies 
that combined topical and systemic antihistamines compared to systemic antihistamines alone 
were ruled out.  Fortunately, the studies yielded by the search were all randomized controlled 
trials. 
 
RESULTS 
 
 Effective outcomes were measured using a scoring system based on nasal or ocular 
allergy symptoms.  The intranasal trials used a scoring system based on the design of the study.  
For example, the Total Nasal Symptom Score (TNSS), which consisted of runny nose, sneezing, 
nasal itching, and nasal congestion to measure the effectiveness of the medications in treating 
allergic rhinitis, was used by three of the published studies for this review.  The TNSS was based 
on a scoring system of 0-3 with “0” representing no symptoms and “3” representing severe 
symptoms.  Since the TNSS was generally consistent in the intranasal studies, overall outcomes 
were combined.  The ocular trials were based on a scoring assessment of conjunctival redness 
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and itching.  Although the two studies measured the same reaction and were useful in 
determining the results of this review, the scoring methods differed and each study outcome had 
to be analyzed individually. 
The majority of the studies were of good quality with a sizeable number of subjects.  A 
single study in this trial used only 26 patients as part of is subject group.  That same study was 
vague in reporting on its methods and details.  The other studies clearly reported the flow of the 
participants through the trials, reported a large enough sample size, and utilized randomization 
methods.  Most of the trials occurred within a relatively short time frame with the longest being 
35 days and the shortest being two weeks.  Two of the intranasal studies were designed in a 
similar fashion with the objective of the most recent one, referred to as ACT II (Azelastine 
Cetirizine Trial), conducted to confirm the results of the first study referred to as ACT I. 
 Seven potentially relevant studies were screened and identified.  Of these, six were 
included in the systematic review.  Table 2 summarizes the included studies and provides 
information on patients, interventions, and outcomes. 
 With the exception of the Korsgren et al study, details of the intervention and comparison 
groups were available from the papers.  The interventions were similar in the studies in that they 
were effective in treating allergy driven symptoms.   Korsgren et al was unique with regards to 
the fact that they used an intranasal formulation of cetirizine, which is normally taken orally, to 
compare the effects of the medication.  Table 3 lists a comparative evaluation of overall nasal 
symptom scoring per study methods. 
 Korsgren et al studied the effects of oral cetirizine compared to an intranasal formulation 
of cetirizine in treating allergic rhinitis.  This study randomized 36 patients into two treatment 
groups over three 12-day treatment periods separated by two-week washout periods.2  Thirty-five 
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subjects received oral cetirizine, 34 received intranasal cetirizine, and 35 received placebo.2  
Using a Total Nasal Symptom Scoring Scale (TNSS), scores were recorded during each 
treatment period.  This study directly exposed the patient to a seasonal allergen during each 
treatment period.2  The trial reported the topical cetirizine group to have a mean TNSS of 1.50 in 
the morning, 3.76 ten minutes after the allergen challenge, and 1.51 in the evening.2  The oral 
cetirizine group showed a mean TNSS of 1.14 in the morning, 3.25 ten minutes after the allergen 
challenge, and 1.14 in the evening.  The placebo group reported a mean TNSS of 1.26 in the 
morning, 5.15 ten minutes after the allergen challenge, and 1.19 in the evening.2 
 In 1995, Charpin et al investigated the effects of azelastine nasal spray compared to oral 
cetirizine.  This trial randomized 129 patients into two treatment groups.  Using a Total 
Symptom Score of the Investigator (TSSI), they found negligible improvements in the cetirizine 
group (n=56) over the azelastine group (n=54).  From baseline assessments, the azelastine group 
showed a 47% decrease in TSSI and there was a 55% decrease in the cetirizine group.  
Additionally, at day 14 the TSSI showed a 61% decrease for azelastine groups and 67% decrease 
for cetirizine groups.3  When patients rated their symptoms according to a daily self-assessment 
scoring sheet provided by the study and labeled as the Visual Analogue Scale (VAS), the VAS 
recordings of individual symptoms showed that azelastine was significantly better than cetirizine 
for the relief of nasal stuffiness (azelastine -13.97 ± 1.15; cetirizine -9.38 ± 0.94) and rhinorrhea 
(azelastine -14.71 ± 0.79; cetirizine -11.74 ± 0.94).3 
 The Berger et al (ACT II) and Corren et al (ACT I) papers provided near similar 
methods, interventions, and outcomes despite utilizing different treatment population groups.  
Corren et al randomized 307 patients to either receive azelastine (n=152) and a placebo pill or 
placebo nasal spray and cetirizine (n=155).4  They compared using azelastine intranasal spray to 
13 
 
that of cetirizine oral medication in the treatment of seasonal allergic rhinitis. Patients were 
studied over a two-week treatment period in both studies.  Using the Total Nasal Symptom Score 
(TNSS), Corren et al found that, the TNSS demonstrated overall improvement via a decrease in 
the score throughout the two week study.  There was a 29.3% improvement with azelastine nasal 
spray compared to one of 23.0% with cetirizine relative to baseline assessments.4  The onset of 
action was similar at 15 minutes for both azelastine and cetirizine, but at 60 minutes and 240 
minutes, improvements in TNSS favored the azelastine group.4 
 The Berger et al (ACT II) study randomized a total of 354 patients to be included in the 
trial.  Like the ACT I study, one group was randomized to receive azelastine nasal spray (n=179) 
and a placebo pill and the other group received cetirizine (n=175) and a placebo nasal spray.5  
There was a 24.2% improvement with azelastine nasal spray and a 19.2% improvement with 
cetirizine from baseline symptom assessments, with both groups experiencing increased 
improvements of TNSS throughout the duration of the trial.5   
 Horak et al performed a 2006 study in Vienna, Austria comparing the effects of 
azelastine nasal spray and desloratadine tablets.  Forty-five patients completed the randomized 
double-blinded placebo controlled study.  The participants were randomized into three groups 
with azelastine nasal spray (n=15) and a placebo tablet in one group, desloratadine (n=16) and a 
placebo nasal spray in another, and a placebo nasal spray and placebo tablet (n=15) in the final 
group.6  Horak et al used a Major Nasal Symptom Score (MNSS) to evaluate the effectiveness of 
the medications.  MNSS incorporates the total scores of sneezing, rhinorrhea, and nasal itching.6  
Results of the study show that azelastine was superior to desloratadine in decreasing MNSS and 
TNSS.  Azelastine showed a -2.1 ± 2.1 change and desloratadine showed a -1.2 ± 2.1 change 
from baseline MNSS symptoms in treating seasonal allergic rhinitis.6   
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 Abelson and Welch evaluated the effectiveness of olopatadine ophthalmic solution to that 
of loratadine in the treatment of allergic conjunctivitis.  Their trial consisted of 29 patients which 
were randomized into two treatment groups.  Groups were to receive one loratadine tablet and 
one drop of olopatadine in one eye and one drop of placebo in the contralateral eye (n=15) or 
placebo tablet and one drop of olopatadine in one eye and placebo in the contralateral eye 
(n=14).7  Subjective itching values were used to measure the effectiveness of the antihistamine 
medications at 3, 7, and 10 minutes in the treatment of allergic conjunctivitis.  Significant 
differences were seen in favor of olopatadine compared to loratadine.  At 3 minutes, itching 
values for loratadine were 0.8 compared to 0.5 for olopatadine.  At 5 minutes, itching values for 
loratadine were 1.2 compared to 0.5 for olopatadine and at 10 minutes the value for loratadine 
was 0.8 and 0.4 for olopatadine.7 
 Crampton evaluated a similar trial comparing ketotifen ophthalmic to desloratadine in 
treating allergic rhinoconjunctivitis.  Eighty two patients were randomized into three separate 
groups.  Groups received either ketotifen and a placebo tablet (n=27), desloratadine and a 
placebo eye drop (n=27), or desloratadine and ketotifen (n=26).8  Crampton used a redness and 
itching scoring system on a scale from 0 to 4 (0 = none to 4 = severe) and a nasal symptom 
scoring system (sneezing, rhinorrhea, post nasal drip, nasal congestion, palatal pruritus) to assess 
seasonal allergic rhinoconjunctivitis.  The study found that ketotifen and ketotifen/desloratadine 
groups had significantly lower ocular itching scores than the loratadine group alone while 
ketotifen alone showed significantly less total ocular redness compared to the other groups.8  At 
10 to 40 minutes, nasal symptom scores were greater in the ketotifen/desloratadine group 
compared to that of ketotifen or desloratadine alone, but at 50 minutes, the group that received 
ketotifen/desloratadine had better results than ketotifen alone.8 
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DISCUSSION 
 
 The primary goal of this review was to examine the effectiveness of topical 
antihistamines in comparison to the effectiveness of systemic antihistamines with regards to the 
treatment of seasonal allergy symptoms.  This systematic review provides support for the use of 
topical antihistamines over systemic antihistamines in treating seasonal allergic 
rhinoconjunctivitis.   
 Comparisons between antihistamines remains a difficult area to search due to the dearth 
of completed studies comparing the delivery systems for antihistamines.  Significant attempts 
were made to identify studies in any language.  Currently, the standard therapy for seasonal 
allergies begins with intranasal corticosteroids and then usually follows with oral antihistamines.  
Many people have difficulty adhering to the daily regimen of using intranasal steroids for the 
desired effect of treating seasonal allergies.  Secondly, oral antihistamines have proven to be 
beneficial but require systemic absorption and can render a patient more prone to unwanted side 
effects.  With the exception of Charpin et al, the reviewed studies have shown topical 
antihistamines providing a greater effect on symptoms than oral antihistamines.   
 Patients in all the studies were healthy without any co-morbid conditions.  Ages of the 
subjects ranged anywhere from 12 to 74 years old.  All were required to have a history of 
seasonal allergies and either underwent allergen skin testing or had a documented positive 
allergy skin test. 
 Corren et al conducted their study in the fall of 2004.  Berger et al conducted their 
multicenter trial during the 2005 spring season.  Charpin et al did not specify whether the 
patients were directly exposed with allergens to elicit an allergic response or whether their study 
was conducted during a specific season of the year.  Horak et al used the Vienna Challenge 
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Chamber (VCC) to expose the trial population to a controlled grass pollen concentration.  VCC 
is a validated environmental exposure unit that allows allergen challenges in a controlled 
environment.6  Abelson et al and Crampton used a conjunctival allergen challenge model in 
which the eyes were directly exposed to seasonal allergens to elicit an allergic response.   
 Korsgren et al conducted their study during the pollen-free Scandinavian winter months 
and directly treated their patients with controlled allergen challenges.2  Also, determining which 
groups received placebo was difficult to identify from the study.  The assumption was made that 
during each treatment period, the patients would switch to receiving a different modality of the 
drug.  For example, if the subject had received oral cetirizine and an intranasal placebo in the 
first treatment group, they would then receive either a placebo tablet and cetirizine intranasal 
spray or placebo tablet and placebo intranasal spray for the successive treatment periods.   
 In the ACT I and ACT II studies, the most common side effect reported for azelastine 
was a bitter taste.4, 5The most common reported side effect for cetirizine was somnolence.3-6  No 
serious adverse reactions were reported in any of the studies. 
 There is no accepted ideal scoring system in assessing the outcomes of allergies.  The 
Total Nasal Symptom Scoring (TNSS) system appears to be the most commonly used outcome 
method in quantifying an allergic rhinitis response among patients.  The ocular studies used their 
own assessment scales in determining symptoms for allergic conjunctivitis.  Abelson et al placed 
more emphasis on itching when assessing for ocular symptoms while Crampton used an equally 
weighted itching and redness scale.  
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CONCLUSION 
 
These studies used specific antihistamine medications to compare treatment options for 
seasonal allergic rhinoconjunctivitis.   Since all the topical and oral antihistamines that are 
available were not tested, we can only generalize the effectiveness of the other untested 
medications since the main mechanism of action is similar for these classes of drugs.   
Presently, patients are prescribed intranasal corticosteroids as the initial treatment of 
choice with oral antihistamines to be used on an as-needed basis.  While long term results may 
be similar in effectiveness, most patients prefer immediate relief from their symptoms as well as 
decreased likelihood of systemic side effects.  Based on this literature review, topical 
antihistamines are a reasonable treatment of choice for seasonal allergic rhinoconjunctivitis.  
Future studies would be worthwhile to compare other modalities of treatment for seasonal 
allergies.  The development of a standardized scoring system to evaluate allergic symptoms 
would also be beneficial for future research studies. 
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Table 1 │ Common Antihistamines 
Oral Antihistamines 
Brand name (generic) 
Intranasal Antihistamines 
Brand name (generic) 
Ocular Antihistamines 
Brand name (generic) 
Claritin (loratadine) Astelin (azelastine hydrochloride) Zaditor (ketotifen) 
Clarinex (desloratadine) Astepro (azelastine hydrochloride) Optivar (azelastine hydrochloride) 
Allegra (fexofenadine) Patanase (olopatadine) Patanol (olopatadine) 
Zyrtec (cetirizine)  Pataday (olopatadine) 
Xyzal (levocetirizine) 
Benadryl (diphenhydramine)* 
 Elestat (epinastine) 
*1st generation antihistamine 
 
Table 2 │ Study Characteristics of Trials Analyzed in Systematic Review 
Article Patients/Populati
on 
Intervention Outcome 
Measures 
Results 
Abelson M. and 
Welch D., 2000 
Allergic 
conjunctivitis. n=29. 
Treatment of allergic 
conjunctivitis with 
olopatadine 
ophthalmic solution 
Subjective itching 
scale measured at 3, 
7, and 10 minutes. 
Difference was seen 
in favor of Patanol 
at 3, 7, and 10 
minutes. 
Berger et al, 2006 Seasonal allergic 
rhinitis.  Ages 12-74. 
n=360. 
Treatment of allergic 
rhinitis with 
azelastine nasal 
spray. 
Total nasal symptom 
scoring (TNSS) 
Improvements in the 
TNSS and 
individual 
symptoms favored 
azelastine over 
cetirizine. 
Charpin et al, 
1995 
Seasonal allergic 
rhinitis.  Ages 12-60. 
n=129 
Treatment of allergic 
rhinitis with 
azelastine nasal 
spray. 
Total symptom score 
of the investigator 
(TSSI) and patient 
assessed visual 
analogue scale (VAS) 
Slight overall 
improvement of 
cetirizine with TSSI 
but improvements 
seen with azelastine 
with VAS. 
Corren et al, 2005 Seasonal allergic 
rhinitis.  Ages 12-74.  
n=307 
Treatment of allergic 
rhinitis with 
azelastine nasal 
spray. 
Total nasal symptom 
scoring (TNSS) 
Azelastine spray 
improved the 
instantaneous TNSS 
compared with 
cetirizine 
Crampton, H., 
2003 
Eligible subjects 
were >18 years. 
Rhinoconjunctivitis. 
n=80 
Treatment of allergic 
conjunctivitis with 
ketotifen 
Redness and itching 
scoring on a scale of 
0-4 (0 = none, 4 = 
severe) 
Ketotifen 
ophthalmic solution 
decreased the signs 
and symptoms of 
ocular and nasal 
allergic 
rhinoconjunctivitis 
Horak, et al, 2006 Seasonal allergic 
rhinitis.  Ages 18-55. 
n=45 
Treatment of 
seasonal allergic 
rhinitis with 
azelastine 
Major nasal symptom 
score (MNSS), total 
nasal symptom score 
(TNSS) 
Azelastine spray 
improved MNSS 
and TNSS compared 
to desloratadine 
Korsgren et al, 
2007 
Seasonal allergic 
rhinitis.  n=36 
Treatment of 
seasonal allergic 
rhinitis with 
cetirizine 
Total nasal symptom 
score (TNSS) 
Cetirizine intranasal 
spray showed an 
improvement of 
TNSS compared to 
oral cetirizine 
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Table 3 │ Overall Total Nasal Symptom Scoring 
Study Scoring Method Topical 
Antihistamine/Overall 
symptom score or 
percentage decrease 
Oral 
Antihistamine/Overall 
symptom score or 
percentage decrease 
Berger et al Total Nasal Symptom Score Azelastine Nasal Spray/ 24.2% 
decrease in nasal symptoms 
Cetirizine/ 19.2% decrease in 
nasal symptoms 
Charpin et al Total Symptom Score of the 
Investigator. 
Azelastine Nasal Spray/ 61% 
decrease in nasal symptoms 
Cetirizine/ 67% decrease in 
nasal symptoms 
Corren et al Total Nasal Symptom Score Azelastine Nasal Spray/ 29.3% 
decrease in nasal symptoms 
Cetirizine/ 23.0% decrease in 
nasal symptoms 
Horak et al Major Nasal Symptom 
Score 
Azelastine Nasal Spray/ 2.1 
reduction in the overall mean 
score 
Desloratadine/ 1.2 reduction in 
the overall mean score 
Korsgren et al Total Nasal Symptom Score Intranasal cetirizine/ 3.76 overall 
mean total symptom score 
Oral cetirizine/ 3.25 overall 
mean total symptom score 
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